Advertisement

Metabolic stroke in a patient with bi-allelic OPA1 mutations

  • Ayelet ZeremEmail author
  • Keren Yosovich
  • Yael Cohen Rappaport
  • Stephanie Libzon
  • Lubov Blumkin
  • Liat Ben-Sira
  • Dorit Lev
  • Tally Lerman-Sagie
Original Article
  • 45 Downloads

Abstract

OPA1 related disorders include: classic autosomal dominant optic atrophy syndrome (ADOA), ADOA plus syndrome and a bi-allelic OPA1 complex neurological disorder. We describe metabolic stroke in a patient with bi-allelic OPA1 mutations. A twelve-year old girl presented with a complex neurological disorder that includes: early onset optic atrophy at one year of age, progressive gait ataxia, dysarthria, tremor and learning impairment. A metabolic stroke occurred at the age of 12 years. The patient was found to harbor a de novo heterozygous frame shift mutation c.1963_1964dupAT; p.Lys656fs (NM_015560.2) and a missense mutation c.1146A > G; Ile382Met (NM_015560.2) inherited from her mother. The mother, aunt, and grandmother are heterozygous for the Ile382Met mutation and are asymptomatic. The co-occurrence of bi-allelic mutations can explain the severity and the early onset of her disease. This case adds to a growing number of patients recently discovered with bi-allelic OPA1 mutations presenting with a complex and early onset neurological disorder resembling Behr syndrome. To the best of our knowledge metabolic stroke has not been described before as an OPA1 related manifestation. It is important to be aware of this clinical feature for a prompt diagnosis and consideration of available treatment.

Keywords

Mitochondrial disease Neurodegenerative disorder Optic atrophy Behr syndrome Metabolic stroke Next generation sequencing 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest interests.

Informed consent

Informed consent was obtained from the parents for publication in this study.

References

  1. Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferré M, Guillet V, Gueguen N, Loiseau D, MAP C, Verny C, Procaccio V, Lenaers G, Reynier P (2009) OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 41:1855–1865CrossRefGoogle Scholar
  2. Bonifert T, Karle KN, Tonagel F, Batra M, Wilhelm C, Theurer Y, Schoenfeld C, Kluba T, Kamenisch Y, Carelli V, Wolf J, Gonzalez MA, Speziani F, Schule R, Zuchner S, Schols L, Wissinger B, Synofzik M (2014) Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier. Brain 137:2164–2177CrossRefGoogle Scholar
  3. Bonneau D, Colin E, Oca F, Ferre M, Chevrollier A, Gueguen N et al (2014) Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain 137:e301CrossRefGoogle Scholar
  4. Brinjikji W, Swanson JW, Zabel C, Dyck PJ, Tracy JA, Gavrilova RH (2011) Stroke and stroke-like symptoms in patients with mutations in the POLG1 gene. JIMD Rep 1:89–96CrossRefGoogle Scholar
  5. Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, Sadun AA (2009) Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim Biophys Acta 1787:518–528CrossRefGoogle Scholar
  6. Carelli V, Sabatelli M, Carrozzo R, Rizza T, Schimpf S, Wissinger B, Zanna C, Rugolo M, la Morgia C, Caporali L, Carbonelli M, Barboni P, Tonon C, Lodi R, Bertini E (2015) ‘Behr syndrome’ with OPA1 compound heterozygote mutations. Brain 138:e321CrossRefGoogle Scholar
  7. Chao de la Barca JM C, Prunier-Mirebeau D, Amati-Bonneau P, Ferré M, Sarzi E, Bris C, Leruez S et al (2016) OPA1-related disorders: diversity of clinical expression, modes of inheritance and pathophysiology. Neurobiol Dis 90:20–26Google Scholar
  8. Chun BY, Rizzo JF (2017) Dominant optic atrophy and Leber's hereditary optic neuropathy: update on clinical features and current therapeutic approaches. Semin Pediatr Neurol 24:129–134CrossRefGoogle Scholar
  9. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P et al (2000) Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26:207–210CrossRefGoogle Scholar
  10. Ganetzky RD, Falk MJ (2018) 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab 123:301–308CrossRefGoogle Scholar
  11. Hikmat O, Eichele T, Tzoulis C, Bindoff LA (2017) Understanding the epilepsy in POLG related disease. Int J Mol Sci 18(9) pii:E1845Google Scholar
  12. Kjer P (1957) Hereditary infantile optic atrophy with dominant transmission. Acta Genet Stat Med 7:290–291Google Scholar
  13. Kuriyama M, Igata A (1985) Mitochondrial encephalopathy, lactic acidosis, and strokelike syndrome (MELAS). Ann Neurol 18:625–626CrossRefGoogle Scholar
  14. Liao C, Ashley N, Diot A, Morten K, Phadwal K, Williams A, Fearnley I, Rosser L, Lowndes J, Fratter C, Ferguson DJP, Vay L, Quaghebeur G, Moroni I, Bianchi S, Lamperti C, Downes SM, Sitarz KS, Flannery PJ, Carver J, Dombi E, East D, Laura M, Reilly MM, Mortiboys H, Prevo R, Campanella M, Daniels MJ, Zeviani M, Yu-Wai-Man P, Simon AK, Votruba M, Poulton J (2017) Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations. Neurology 88:131–142CrossRefGoogle Scholar
  15. Nasca A, Rizza T, Doimo M, Legati A, Ciolfi A, Diodato D, Calderan C, Carrara G, Lamantea E, Aiello C, di Nottia M, Niceta M, Lamperti C, Ardissone A, Bianchi-Marzoli S, Iarossi G, Bertini E, Moroni I, Tartaglia M, Salviati L, Carrozzo R, Ghezzi D (2017) Not only dominant, not only optic atrophy: the clinical spectrum associated with OPA1 mutations. Orphanet J Rare Dis 12:89CrossRefGoogle Scholar
  16. Roubertie A, Leboucq N, Picot MC, Nogue E, Brunel H, Le Bars E (2015) Neuroradiological findings expand the phenotype of OPA1-related mitochondrial dysfunction. J Neurol Sci 349:154–160CrossRefGoogle Scholar
  17. Rubegni A, Pisano T, Bacci G, Tessa A, Battini R, Procopio E, Giglio S, Pasquariello R, Santorelli FM, Guerrini R, Nesti C (2017) Leigh-like neuroimaging features associated with new biallelic mutations in OPA1. Eur J Paediatr Neurol 21:671–677CrossRefGoogle Scholar
  18. Sagie S, Lerman-Sagie T, Maljevic S, Yosovich K, Detert K, Chung SK, et al (2018) Expanding the phenotype of TRAK1 mutations: hyperekplexia and refractory status epilepticus. Brain 1;141(7):e55Google Scholar
  19. Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, Wong LJ, Scaglia F (2011) Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations. Mol Genet Metab 103:383–387CrossRefGoogle Scholar
  20. Spiegel R, Saada A, Flannery PJ, Burte F, Soiferman D, Khayat M et al (2016) Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophyassociated with a homozygous OPA1 mutation. J Med Genet 53:12s–131sGoogle Scholar
  21. Testai FD, Gorelick PB (2010) Inherited metabolic disorders and stroke part 1. Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and Strokelike episodes. Arch Neurol 67:19–24Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Metabolic Neurogenetic Service, Pediatric Neurology UnitWolfson Medical CenterHolonIsrael
  2. 2.Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  3. 3.Metabolic Neurogenetic Service, Genetics InstituteWolfson Medical CenterHolonIsrael
  4. 4.Division of Pediatric Radiology, Department of Radiology, Dana Children’s HospitalTel-Aviv Medical CenterTel AvivIsrael

Personalised recommendations